Page last updated: 2024-12-06

2-(dimethylamino)ethyl methacrylate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-(dimethylamino)ethyl methacrylate, also known as DMAEMA, is a monomer commonly used in the synthesis of polymers. It is a colorless liquid with a characteristic amine odor. DMAEMA is readily polymerized via free radical polymerization to form poly(2-(dimethylamino)ethyl methacrylate) (PDMAEMA), a cationic polymer with a variety of applications. DMAEMA can be synthesized by reacting methacryloyl chloride with 2-(dimethylamino)ethanol. PDMAEMA is a water-soluble polymer that exhibits pH-sensitive properties, meaning its charge and solubility change with pH. This unique characteristic makes it a valuable material in various fields, including drug delivery, gene therapy, and biocompatible coatings. PDMAEMA-based polymers have been studied for their ability to encapsulate and deliver drugs, protect sensitive molecules from degradation, and modify surfaces for improved biocompatibility. The presence of the tertiary amine group in DMAEMA contributes to its ability to form complexes with various molecules, including biomolecules like DNA and proteins. This property makes PDMAEMA suitable for applications in gene delivery, where the polymer can complex with DNA to form nanoparticles that can be taken up by cells.'

2-(dimethylamino)ethyl methacrylate: reducing agent; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID17869
CHEMBL ID1883484
SCHEMBL ID14984
MeSH IDM0142613

Synonyms (72)

Synonym
LS-13486
2-propenoic acid, 2-methyl-, 2-(dimethylamino)ethyl ester
2-(n,n-dimethylamino)ethyl methacrylate
wln: 1uy1&vo2n1&1
n,n-(dimethylamino)ethyl methacrylate
nsc-20959
usaf rh-3
ethanol, methacrylate
n,n-dimethylethanolamine methacrylate
.beta.-(dimethylamino)ethyl methacrylate
2-dimethylaminoethyl methacrylate
.beta.-(n,n-dimethylamino)ethyl methacrylate
2-(dimethylamino)ethyl methacrylate
methacrylic acid, 2-(dimethylamino)ethyl ester
(dimethylamino)ethyl methacrylate
2867-47-2
nsc20959
dimethylaminoethyl methacrylate
hsdb 5464
2-dimethylaminoethylester kyseliny methakrylove [czech]
brn 1757048
n,n-dimethylaminoethyl methacrylate
ccris 872
2-(dimethylamino)ethyl 2-methyl-2-propenoate
beta-dimethylaminoethyl methacrylate
einecs 220-688-8
un2522
ethanol, 2-(dimethylamino)-, methacrylate
nsc 20959
ageflex fm-1
2-(dimethylamino)ethyl methacrylate, contains 700-1000 ppm monomethyl ether hydroquinone as inhibitor, 98%
NCGC00164097-01
dmaema
methacrylic acid 2-(dimethylamino)ethyl ester
M0082
NCGC00164097-02
unii-o0v97pv2g1
2-dimethylaminoethyl methacrylate [un2522] [poison]
o0v97pv2g1 ,
4-04-00-01432 (beilstein handbook reference)
ec 220-688-8
2-dimethylaminoethylester kyseliny methakrylove
cas-2867-47-2
NCGC00259243-01
dtxcid307504
tox21_201694
dtxsid1027504 ,
AKOS005207198
25154-86-3
AM84885
2-(dimethylamino)ethyl 2-methylprop-2-enoate
methacryloyloxyethyl-n,n-dimethylamine
n,n-di-methylaminoethyl methacrylate
dimethylaminoethylmethacrylate
SCHEMBL14984
n,n-dimethylaminoethyl methacrylate [hsdb]
dimethylaminoethyl methacrylate [inci]
un 2522
2-(dimethylamino)ethyl 2-methylacrylate #
sipomer 2m1m (salt/mix)
2-methyl-2-propenoic acid 2-(dimethylamino)ethyl ester
CHEMBL1883484
mfcd00008589
J-506394
2-(dimethylamino)ethyl methacrylate, (stabilized with mehq)
2-(dimethylamino)ethyl methacrylate, european pharmacopoeia (ep) reference standard
basic butylated methacrylate copolymer imp. c (ep); 2-(dimethylamino)ethyl methacrylate; basic butylated methacrylate copolymer impurity c
2-(dimethylamino)ethyl methacrylate (stabilized with mehq)
2-(dimethylamino)ethyl methacrylate (stabilized with 0.2per cent 4-methoxyphenol)
Q27285181
2-(dimethylamino)ethyl methylpropenoate
AT33769

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Cytotoxicity of photocurable composite resins is a key issue for their safe use in dental restoration."( Correlating cytotoxicity to elution behaviors of composite resins in term of curing kinetic.
Cai, Q; Cao, M; Li, L; Meng, J; Yang, H, 2017
)
0.46

Bioavailability

ExcerptReferenceRelevance
" β-Cyclodextrin accelerates the in vivo thymol absorption rate compared with the free drug; the thymol half-life is still long."( Improvement of thymol properties by complexation with cyclodextrins: in vitro and in vivo studies.
Boatto, G; Bosi, P; Carta, A; Gavini, E; Giunchedi, P; Nieddu, M; Rassu, G; Trevisi, P, 2014
)
0.4

Dosage Studied

ExcerptRelevanceReference
" The results indicate that prolonged polymer storage leads to important charge loss effects, resulting in increased dosage requirements for satisfactory dewatering performance."( Implications and remediations of DMAEA-Q type polymer hydrolysis in wastewater treatment plants.
Cauwenberghs, J; Curvers, D; Pelicaen, J; Saveyn, H; Thoeye, C; Van der Meeren, P, 2010
)
0.36
"The combination therapy which has been proposed as the strategy for the cancer treatment could achieve a synergistic effect for cancer therapies and reduce the dosage of the applied drugs."( An improved method in fabrication of smart dual-responsive nanogels for controlled release of doxorubicin and curcumin in HT-29 colon cancer cells.
Abedi, F; Akbarzadeh, A; Baradaran, B; Davaran, S; Hekmati, M; Moghaddam, SV, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency39.81070.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency9.46230.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency87.22810.001530.607315,848.9004AID1224841
estrogen nuclear receptor alphaHomo sapiens (human)Potency6.98170.000229.305416,493.5996AID588513; AID743075
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency27.30600.000627.21521,122.0200AID651741
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (301)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (1.66)18.7374
1990's25 (8.31)18.2507
2000's84 (27.91)29.6817
2010's161 (53.49)24.3611
2020's26 (8.64)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 41.32

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index41.32 (24.57)
Research Supply Index5.75 (2.92)
Research Growth Index5.38 (4.65)
Search Engine Demand Index61.28 (26.88)
Search Engine Supply Index2.01 (0.95)

This Compound (41.32)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.32%)5.53%
Reviews1 (0.32%)6.00%
Case Studies1 (0.32%)4.05%
Observational0 (0.00%)0.25%
Other309 (99.04%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]